



Principal shareholders issue call options to senior executives in SyntheticMR

SyntheticMR AB (publ) ("SyntheticMR") announced today that leading executives (CEO and Head of US region) agreed on the purchase of a total of 300 000 call options. The options are issued by SyntheticMR's principal shareholders (Nortal Investments AB, managed by Staffan Persson), founder (Marcel Warntjes) and Chairman of the Board (Johan Sedihh), which means there is no dilution for other shareholders. Holders have the right to acquire one (1) share in SyntheticMR for each call option.

The duration of the incentive program is almost 5 years and exercising the call options can take place between June 2023 and June 2026. The exercise price per share shall amount to SEK 50. The price of the call option has been set at SEK 15 and has been calculated using Black & Scholes' valuation model.

As of today the issuers of the options own a total of 17 206 890 shares in SyntheticMR, equivalent of 42,6 percent of the shares and votes.

This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-08-2021 08:16 CET.

For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com.

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single 6-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI MSK provides multiple contrast images and quantitative data for MSK anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI MSK is CE-marked and FDA 510(k) pending. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com